Investors

Overview

CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective ways to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. We have a commercial product, PIXUVRI®, available in certain markets in Europe, as well as a diverse late-stage development pipeline that we believe will drive future growth of our company. We are headquartered in Seattle, Washington, with offices in London and Milan. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$2.27 - 0.01 (0.44%)
Day High:$2.33
Day Low:$2.25
Volume:918,600
10/17/144:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345
invest@ctiseattle.com


CTI Life Sciences Limited, Milan Branch
Laura Villa
T +1 39 02 94751572
T +1 206-272-4155 (U.S. only)
LVilla@cti-lifesciences.com
 

Recent News

MORE
DateTitle 
Oct 20, 2014CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014
SEATTLE, Wash., Oct. 20, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter 2014 financial results on Wednesday, October 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Wednesd... 
Printer Friendly Version
Sep 17, 2014CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®
- Total Deal Valued at up to Approximately $133.5 Million; Approximately $18.1 million Upfront - - CTI Retains 100% Commercialization Rights to PIXUVRI in U.S. and Certain E.U. Territories - - Conference Call Scheduled for Today at 8:30 a.m. EDT - SEATTLE, Sept. 17, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) and Servier today jointly announced that they have entered into an exclusive license and collaboration agreement to develop and commercialize PIXUVRI® (... 
Printer Friendly Version
Aug 07, 2014FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-... 
Printer Friendly Version

Events

MORE
DateTitle
Sep 17, 2014
CTI BioPharma Conference
Sep 16, 2014
CTI Corporate Presentation
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.